Annals of Hematology Hematology

A randomized, two-armed, double-blind, single-dose, cross-over, bioequivalence clinical trial to compare pharmacokinetic parameters and safety of recombinant human factor VIII with Fc fusion produced by AryoGen Pharmed Company versus Elocta® (reference product) in previously treated patients with severe haemophilia A

Aziz Eghbali, Peyman Eshghi, Gholamreza Toogeh, Samin Alavi, Zahra Badiei, Majid Ghanavat, Mohammadreza Bordbar, Asghar Bazrafshan, Katayoon Karimi, Minoo Ahmadinejad, Araz Sabzvari, Hamidreza Kafi
Springer Nature · 2025-02-01 · DOI 10.1007/s00277-025-06242-z

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →